Deoxyribonuclease is prognostic in patients undergoing transcatheter aortic valve replacement
Andreas Mangold(Medical University of Vienna), Michael Lichtenauer(University of Salzburg), P. Christian Schulze(Temple College), Alexander Lauten(German Centre for Cardiovascular Research), Matthias Hammerer(University of Salzburg), Marcus Franz(Jena University Hospital), Thomas M. Hofbauer(Medical University of Vienna), Bernhard Wernly(Paracelsus Medical University), Evelyne Wohlschläger‐Krenn(RHI Magnesita (Austria)), Brunilda Alushi(Deutsches Herzzentrum der Charité), Uta C. Hoppe(Baker Heart and Diabetes Institute), Johanna Nechvile(Medical University of Vienna), Tyler Artner(Medical University of Vienna), Noel G. Panagiotides(Medical University of Vienna), Iréne Lang(Medical University of Vienna), Moritz Mirna(Paracelsus Medical University), Anna S. Ondracek(Medical University of Vienna), Dzeneta Fejzic(University of Salzburg)
Cited by 3
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889